Published in Cancer Res on November 01, 1991
Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer (1993) 2.10
Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol (2009) 1.32
Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression. Br J Cancer (1996) 0.95
Mutagenesis in monkey cells of a vector containing a single d(GPG) cis-diamminedichloroplatinum(II) adduct placed on codon 13 of the human H-ras proto-oncogene. Nucleic Acids Res (1994) 0.95
Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer. Mol Cancer Ther (2008) 0.89
Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testis. Am J Pathol (2000) 0.88
Potential roles for prions and protein-only inheritance in cancer. Cancer Metastasis Rev (2012) 0.82
Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistance. Cytotechnology (1998) 0.75
The sequence of the human genome. Science (2001) 101.55
The genome sequence of Drosophila melanogaster. Science (2000) 74.32
Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology (1999) 3.06
Development and evaluation of a multiplex PCR assay for rapid detection of toxigenic Vibrio cholerae O1 and O139. FEMS Immunol Med Microbiol (1998) 2.98
The role of DNA mismatch repair in platinum drug resistance. Cancer Res (1996) 2.88
Effect of transradial access on quality of life and cost of cardiac catheterization: A randomized comparison. Am Heart J (1999) 2.72
Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol (1990) 2.60
Neuroleptic malignant syndrome. Med Clin North Am (1993) 2.56
Bcl2 is the guardian of microtubule integrity. Cancer Res (1997) 2.51
A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res (1999) 2.50
The role of DNA mismatch repair in drug resistance. Clin Cancer Res (1998) 2.49
Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant (2006) 2.48
Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells (1990) 2.43
UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst (1996) 2.39
Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res (1996) 2.37
Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol (1999) 2.29
Temporal shifts in traits of Vibrio cholerae strains isolated from hospitalized patients in Calcutta: a 3-year (1993 to 1995) analysis. J Clin Microbiol (1996) 2.21
Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab (2000) 2.15
A critical appraisal of methods to grade transplant glomerulitis in renal allograft biopsies. Am J Transplant (2010) 2.14
Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer (1993) 2.10
Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry (1986) 2.09
Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst (1990) 2.06
Lethal catatonia. Am J Psychiatry (1986) 2.03
Overexpression of metallothionein confers resistance to anticancer drugs. Science (1988) 2.03
Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-beta precede bleomycin-induced pulmonary fibrosis in mice. J Pharmacol Exp Ther (1988) 2.01
Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II). Biochemistry (1983) 1.96
Molecular analysis of non-O1, non-O139 Vibrio cholerae associated with an unusual upsurge in the incidence of cholera-like disease in Calcutta, India. J Clin Microbiol (1998) 1.94
Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res (1981) 1.91
Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res (1994) 1.89
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene (1994) 1.88
Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J Natl Cancer Inst (1997) 1.88
SPARC deficiency leads to early-onset cataractogenesis. Invest Ophthalmol Vis Sci (1998) 1.83
Identification of deoxyribonuclease II as an endonuclease involved in apoptosis. Arch Biochem Biophys (1993) 1.75
Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells. Eur J Cancer Clin Oncol (1989) 1.68
Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest (1991) 1.62
Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res (1988) 1.61
Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst (1997) 1.58
Neuroleptic malignant syndrome. Psychopharmacol Bull (1988) 1.57
Endogenous complement C3 synthesis in immune complex nephritis. Lancet (1993) 1.57
A system in mouse liver for the repair of O6-methylguanine lesions in methylated DNA. Nucleic Acids Res (1981) 1.56
cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res (1988) 1.56
Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol (2000) 1.55
Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J Biol Chem (1984) 1.54
Genomic structures and population histories of linguistically distinct tribal groups of India. Hum Genet (2001) 1.53
Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer. Obstet Gynecol (1993) 1.52
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res (1997) 1.50
Resurgence of Vibrio cholerae O139 Bengal with altered antibiogram in Calcutta, India. Lancet (1996) 1.49
Apoptosis in an interleukin-2-dependent cytotoxic T lymphocyte cell line is associated with intracellular acidification. Role of the Na(+)/H(+)-antiport. J Biol Chem (1995) 1.48
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res (1997) 1.47
Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med (1982) 1.46
Unique organization of the CTX genetic element in Vibrio cholerae O139 strains which reemerged in Calcutta, India, in September 1996. J Clin Microbiol (1997) 1.46
Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol (1999) 1.44
Circulating immunoglobulin complexes in Wegener's granulomatosis. Am J Med (1976) 1.43
Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer Res (1998) 1.40
High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis. J Pharmacol Exp Ther (1987) 1.39
Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol (1992) 1.39
Metallothionein protects against the cytotoxic and DNA-damaging effects of nitric oxide. Proc Natl Acad Sci U S A (1995) 1.37
Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res (1996) 1.34
Etoposide-induced apoptosis in human HL-60 cells is associated with intracellular acidification. Cancer Res (1993) 1.32
Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res (1988) 1.31
Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res (1985) 1.30
Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res (1997) 1.29
Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res (1987) 1.29
Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys (1987) 1.29
Lack of metabolism as the biochemical basis of bleomycin-induced pulmonary toxicity. Proc Natl Acad Sci U S A (1983) 1.29
Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol (2001) 1.28
Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun (1990) 1.27
Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer (2001) 1.26
Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer (1994) 1.26
Endonuclease activation during apoptosis: the role of cytosolic Ca2+ and pH. Biochem Biophys Res Commun (1992) 1.26
Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms. Oncogene (1999) 1.24
Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res (1983) 1.23
Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. Head Neck (1992) 1.22
Molecular epidemiology of reemergent Vibrio cholerae O139 Bengal in India. J Clin Microbiol (1998) 1.22
A polymerase chain reaction-based method to detect cisplatin adducts in specific genes. Nucleic Acids Res (1991) 1.21
Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck (2000) 1.21
Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors. Biochem Pharmacol (1997) 1.20
Free proximal trisomy 21 without the Down syndrome. Clin Genet (1987) 1.19
Interstrand cross-links and sequence specificity in the reaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry (1985) 1.19
Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer (1991) 1.18
Inhibition of ERK attenuates autophagy and potentiates tumour necrosis factor-alpha-induced cell death in MCF-7 cells. J Cell Mol Med (2008) 1.18
Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry (2001) 1.18
DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA. Biochemistry (1989) 1.18
Cancer incidence in the industrial corridor: an update. J La State Med Soc (1998) 1.17
Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol (1993) 1.16
Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res (1987) 1.16
Psychotropic drugs, summer heat and humidity, and hyperpyrexia: a danger restated. Am J Psychiatry (1978) 1.15
Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes. Chem Biol Interact (1987) 1.15
Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody. Int J Cancer (1993) 1.15
Totally implantable system for peritoneal access. J Clin Oncol (1984) 1.15
Deoxyribonuclease IIalpha is required during the phagocytic phase of apoptosis and its loss causes perinatal lethality. Cell Death Differ (2002) 1.15
Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents. Oncogene (2001) 1.15
Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre. Transplant Proc (1997) 1.14
Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis (1994) 1.14
Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol (1987) 1.13